Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Subject is a male between the ages of 18 and 45 or a female less than or equal to 70 years of age

• Females must be past menopause

• Subject is a nonsmoker

• Subject is willing to avoid excessive alcohol consumption during the study and is willing to avoid alcohol entirely for 24 hours prior to drug administration and during PK sampling

• Subject is willing to refrain from consuming grapefruit or grapefruit juice

Exclusion Criteria:

• Subject has a history of multiple/severe allergies to drugs or food

• Subject has donated blood within 4 weeks of starting the study

• Subject has a history of metabolic bone disease, urolithiasis, or bisphosphonate treatment

• Subject has any infections or any condition leading to immune problems, including HIV

• Subject regularly uses illegal drugs

• Subject consumes more than 3 alcoholic beverages per day

• Subject drinks 4 or more caffeinated beverages per day

• Subject uses any prescription or nonprescription medications